Bellicum Pharmaceuticals, Inc. Soared
Wed, Dec 11, 2019 at 05:30 PM
Bellicum Pharmaceuticals, Inc. (BLCM:NASDAQ) soared at $1.13, representing a gain of 40.7%. On Tue 10 Dec 19, BLCM:NASDAQ touched a New 2-Week Low of $0.8. The stock got featured on our News Catalysts scanner on Wed 11 Dec 19 at 08:28 AM in the 'MISCELLANEOUS' category. From Tue 19 Nov 19, the stock recorded 35.71% Up Days and 46.67% Green Days
The stock spiked on Mon 04 Nov 19 at $1.47 with a volume of 4M+, and its share price has been moving sideways in recent weeks.
About Bellicum Pharmaceuticals, Inc. (BLCM:NASDAQ)
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The firm is primarily engaged in the research of cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases.
Top 10 Gainers:
- CTI Industries Corporation (CTIB:NASDAQ), 150.81%
- DPW Holdings, Inc. (DPW:NYSEMKT), 82.39%
- Forward Pharma A/S (FWP:NASDAQ), 69.91%
- Camber Energy, Inc. (CEI:NYSEMKT), 69.42%
- Bellicum Pharmaceuticals, Inc. (BLCM:NASDAQ), 40.72%
- Marinus Pharmaceuticals, Inc. (MRNS:NASDAQ), 37.98%
- Diffusion Pharmaceuticals Inc. (DFFN:NASDAQ), 31.4%
- Immunic, Inc. (IMUX:NASDAQ), 24.62%
- Centogene N.V. (CNTG:NASDAQ), 23.76%
- Neon Therapeutics, Inc. (NTGN:NASDAQ), 23.64%